Search results
Results from the WOW.Com Content Network
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...
2010: Combination of two antibodies against immune control checkpoint to enhance cytotoxic T lymphocytes response and inhibit regulatory T lymphocytes suppressive effect on the immune response. [2] 2012: First oligoclonal antibody combination was approved for use. It is composed of trastuzumab and pertuzumab both targeting HER-2 in breast ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
The safety and efficacy of trastuzumab-containing combination therapies (with chemotherapy, hormone blockers, or lapatinib) for the treatment of metastatic breast cancer. [clarification needed] The overall hazard ratios (HR) for overall survival and progression free survival were 0.82 and 0.61, respectively.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
The Times story also cited a buprenorphine study by researchers in Sweden that looked at “100 autopsies where buprenorphine had been detected.” According to the Times, the study found that “in two-thirds, it was the direct cause of death, mostly in combination with other drugs.” It was a misreading of the study.
Trastuzumab/hyaluronidase, sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing breast ...